Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vancouver-based Cardiome Pharma, a product-focused cardiovascular drug development company, announced that the waiting period under the Hart-Scott-Rodino Act for the collaboration and license agreement with Merck & Co., and a Merck affiliate for development and commercialization of vernakalant, has expired, and the agreement is now effective.
Subscribe to our email newsletter
Vernakalant is an investigational candidate used for the treatment of atrial fibrillation.
As per the terms of the agreement, effectiveness of the agreement triggers an initial payment of $60 million to Cardiome from Merck.
Cardiome Pharma is engaged in the development and commercialisation of novel treatments for disorders of the heart and circulatory system.